Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals Provides Update on Zepzelca® Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® in Gastroesophageal Adenocarcinoma and Zepzelca®
Jazz Pharmaceuticals to Present Research on Epidiolex® and Xywav® Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
